PT2473049T - Inibidores de tirosina quinase de bruton - Google Patents
Inibidores de tirosina quinase de brutonInfo
- Publication number
- PT2473049T PT2473049T PT10814585T PT10814585T PT2473049T PT 2473049 T PT2473049 T PT 2473049T PT 10814585 T PT10814585 T PT 10814585T PT 10814585 T PT10814585 T PT 10814585T PT 2473049 T PT2473049 T PT 2473049T
- Authority
- PT
- Portugal
- Prior art keywords
- bruton
- tyrosine kinase
- kinase inhibitors
- inhibitors
- tyrosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24001109P | 2009-09-04 | 2009-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2473049T true PT2473049T (pt) | 2019-03-04 |
Family
ID=43649668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT10814585T PT2473049T (pt) | 2009-09-04 | 2010-09-03 | Inibidores de tirosina quinase de bruton |
Country Status (15)
Country | Link |
---|---|
US (6) | US8785440B2 (pt) |
EP (2) | EP3461824B1 (pt) |
JP (6) | JP5699149B2 (pt) |
CN (3) | CN102711473B (pt) |
AR (2) | AR078320A1 (pt) |
AU (3) | AU2010289313B2 (pt) |
CA (2) | CA2771822C (pt) |
DK (1) | DK2473049T3 (pt) |
ES (2) | ES2711936T3 (pt) |
HU (1) | HUE043522T2 (pt) |
NZ (1) | NZ598985A (pt) |
PL (1) | PL2473049T3 (pt) |
PT (1) | PT2473049T (pt) |
TW (2) | TWI711610B (pt) |
WO (1) | WO2011029046A1 (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE043522T2 (hu) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
CN103080101A (zh) * | 2010-05-17 | 2013-05-01 | 阵列生物制药公司 | 作为gpr119调节剂的哌啶基取代的内酰胺 |
RU2563644C2 (ru) | 2010-08-20 | 2015-09-20 | Хатчисон Медифарма Лимитед | Пирролопиримидиновые соединения и их применения |
WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
WO2012170976A2 (en) * | 2011-06-10 | 2012-12-13 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
CA2851788C (en) | 2011-10-11 | 2022-11-29 | Dana-Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic bax |
EP2773207B1 (en) | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
JP5976826B2 (ja) * | 2011-11-03 | 2016-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Btk活性阻害剤としての8−フルオロフタラジン−1(2h)−オン化合物 |
AU2012332368A1 (en) * | 2011-11-03 | 2014-05-22 | F. Hoffmann-La Roche Ag | Alkylated piperazine compounds as inhibitors of Btk activity |
WO2013067260A1 (en) * | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Bicyclic piperazine compounds |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CA2862831A1 (en) * | 2012-01-09 | 2013-07-18 | X-Rx, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
CN104662018B (zh) * | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
CN102702110A (zh) * | 2012-05-24 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4-氨基-5,6-二氯嘧啶的制备方法 |
US9353087B2 (en) * | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
KR20150060839A (ko) * | 2012-10-26 | 2015-06-03 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
EA201500393A1 (ru) * | 2012-11-02 | 2016-05-31 | Пфайзер Инк. | Ингибиторы тирозинкиназы брутона |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
HUE031980T2 (en) | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
TWI642657B (zh) | 2013-06-26 | 2018-12-01 | 艾伯維有限公司 | 作為btk抑制劑的初級甲醯胺 |
HUE049281T2 (hu) | 2013-09-13 | 2020-09-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
ES2654051T3 (es) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas |
CA2932608C (en) * | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
CN106661002B (zh) | 2014-08-04 | 2021-06-29 | 纽韦卢森公司 | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物 |
EP3288943B1 (en) | 2015-05-01 | 2022-09-28 | Pfizer Inc. | Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase |
WO2017198050A1 (zh) * | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物 |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
MX2019000884A (es) | 2016-07-21 | 2019-09-04 | Biogen Ma Inc | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. |
TW202233628A (zh) | 2016-08-16 | 2022-09-01 | 英屬開曼群島商百濟神州有限公司 | (s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途 |
FI3500299T3 (fi) | 2016-08-19 | 2024-02-14 | Beigene Switzerland Gmbh | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa |
MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
AU2017368331A1 (en) | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
JOP20190233A1 (ar) * | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
CN111132673A (zh) | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
JP7245229B2 (ja) | 2017-08-21 | 2023-03-23 | ビバーチェ セラピューティクス,インク. | ベンゾスルホニル化合物 |
CN107445981B (zh) * | 2017-08-25 | 2018-06-22 | 牡丹江医学院 | 一种用于防治宫颈炎的活性化合物 |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
CA3084648A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
WO2020043321A1 (en) | 2018-08-31 | 2020-03-05 | Stichting Katholieke Universiteit | Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof |
EP3852879A1 (en) | 2018-09-21 | 2021-07-28 | Pfizer Inc. | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
CN109369513B (zh) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | 一种fbdd常用分子片段的制备方法 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP2023519603A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
CN113416847B (zh) * | 2021-07-05 | 2022-05-31 | 昆明理工大学 | 一种将提钒尾渣资源化、减量化、无害化处理的方法 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6919178B2 (en) * | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
NZ521248A (en) | 2000-03-17 | 2004-04-30 | Bristol Myers Squibb Pharma Co | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
JP2005515173A (ja) | 2001-10-31 | 2005-05-26 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ピリミド[4,5−b]インドール誘導体 |
WO2004065380A1 (en) * | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
CN1835943B (zh) * | 2003-01-14 | 2012-03-07 | 阿伦纳药品公司 | 作为代谢调节剂的1,2,3-三取代的芳基和杂芳基衍生物及其应用 |
ATE437872T1 (de) | 2003-10-14 | 2009-08-15 | Univ Arizona | Proteinkinaseinhibitoren |
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
JP5254620B2 (ja) | 2004-12-03 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Cb1アンタゴニストとしての置換ピペラジン |
EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
US7880002B2 (en) * | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
NZ592990A (en) * | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
CA2634235A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
EP2059305A2 (en) | 2006-07-26 | 2009-05-20 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
EP2270200A3 (en) | 2006-09-11 | 2011-07-13 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
ATE531263T1 (de) | 2006-09-22 | 2011-11-15 | Pharmacyclics Inc | Hemmer der bruton-tyrosinkinase |
WO2009134891A2 (en) | 2008-04-29 | 2009-11-05 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
CL2008000594A1 (es) | 2007-03-02 | 2008-09-05 | Schering Corp | Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades. |
CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
CN101932580B (zh) | 2007-06-01 | 2013-05-22 | 葛兰素史密丝克莱恩有限责任公司 | 咪唑并吡啶激酶抑制剂 |
NZ586916A (en) | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
JP5369183B2 (ja) | 2008-07-16 | 2013-12-18 | ファーマサイクリックス,インク. | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
JP5908728B2 (ja) | 2009-01-06 | 2016-04-26 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法 |
ES2565205T3 (es) | 2009-05-25 | 2016-04-01 | Sandoz Ag | Método para la producción de ceftobiprol medocaril |
EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
HUE043522T2 (hu) | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
US8685880B2 (en) | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
WO2012058645A1 (en) * | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
US9353087B2 (en) * | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
EP3080122B1 (en) * | 2013-12-11 | 2018-10-31 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
CA2932608C (en) * | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
US20170298446A1 (en) | 2014-10-03 | 2017-10-19 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
MX2019000884A (es) * | 2016-07-21 | 2019-09-04 | Biogen Ma Inc | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. |
-
2010
- 2010-09-03 HU HUE10814585A patent/HUE043522T2/hu unknown
- 2010-09-03 DK DK10814585.5T patent/DK2473049T3/en active
- 2010-09-03 AU AU2010289313A patent/AU2010289313B2/en not_active Ceased
- 2010-09-03 EP EP18204302.6A patent/EP3461824B1/en active Active
- 2010-09-03 EP EP10814585.5A patent/EP2473049B1/en active Active
- 2010-09-03 TW TW105123517A patent/TWI711610B/zh active
- 2010-09-03 CN CN201080049405.4A patent/CN102711473B/zh active Active
- 2010-09-03 CN CN201610915859.4A patent/CN107011330B/zh active Active
- 2010-09-03 CA CA2771822A patent/CA2771822C/en active Active
- 2010-09-03 JP JP2012528103A patent/JP5699149B2/ja active Active
- 2010-09-03 PT PT10814585T patent/PT2473049T/pt unknown
- 2010-09-03 CN CN202010504358.3A patent/CN112300172B/zh active Active
- 2010-09-03 AR ARP100103238A patent/AR078320A1/es active IP Right Grant
- 2010-09-03 WO PCT/US2010/047883 patent/WO2011029046A1/en active Application Filing
- 2010-09-03 PL PL10814585T patent/PL2473049T3/pl unknown
- 2010-09-03 US US13/393,192 patent/US8785440B2/en active Active
- 2010-09-03 ES ES10814585T patent/ES2711936T3/es active Active
- 2010-09-03 ES ES18204302T patent/ES2891543T3/es active Active
- 2010-09-03 NZ NZ598985A patent/NZ598985A/xx unknown
- 2010-09-03 CA CA3082212A patent/CA3082212C/en active Active
- 2010-09-03 TW TW099129993A patent/TWI557127B/zh active
-
2014
- 2014-06-26 US US14/316,710 patent/US9249146B2/en active Active
-
2015
- 2015-02-16 JP JP2015027205A patent/JP2015091898A/ja not_active Withdrawn
-
2016
- 2016-01-25 US US15/006,061 patent/US9790229B2/en active Active
- 2016-04-22 AU AU2016202601A patent/AU2016202601B2/en not_active Ceased
-
2017
- 2017-07-13 JP JP2017137018A patent/JP6326533B2/ja active Active
- 2017-09-07 US US15/698,171 patent/US10577374B2/en active Active
-
2018
- 2018-03-07 AU AU2018201668A patent/AU2018201668B2/en not_active Ceased
- 2018-04-16 JP JP2018078461A patent/JP6673969B2/ja active Active
-
2020
- 2020-01-05 JP JP2020000042A patent/JP2020055871A/ja not_active Withdrawn
- 2020-01-21 US US16/748,410 patent/US20200399283A1/en not_active Abandoned
-
2021
- 2021-05-11 AR ARP210101299A patent/AR122069A2/es unknown
-
2022
- 2022-03-04 JP JP2022033553A patent/JP2022071149A/ja active Pending
- 2022-05-12 US US17/743,214 patent/US20230046457A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL266741A (en) | Broton tyrosine kinase inhibitors | |
HUE043522T2 (hu) | Bruton tirozinkináz inhibitorok | |
ZA201301679B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201202552B (en) | Inhibitors of bruton's tyrosine kinase | |
HUS1900014I1 (hu) | Proteinkináz inhibitorok | |
HK1254663A1 (zh) | 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑 | |
ZA201300705B (en) | Inhibitors of bruton's tyrosine kinase | |
IL238571A0 (en) | Broton tyrosine kinase inhibitors, preparations containing them and their uses | |
ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
ZA201004942B (en) | Ptrrolopyrazine kinase inhibitors | |
EP2040546A4 (en) | TYROSINE KINASE INHIBITORS | |
PT2231642E (pt) | Pirimidinas como inibidores de quinase | |
EP2515657A4 (en) | TYROSINE KINASE INHIBITORS | |
ZA200900019B (en) | Tyrosine kinase inhibitors | |
EP2382210A4 (en) | INHIBITORS OF PYRIMIDINEDIAMINE KINASE | |
EP2231152A4 (en) | THIENOPYRANONES AS KINASE INHIBITORS | |
EP2247185A4 (en) | INHIBITORS OF TYROSINE KINASE | |
AU2013276959B2 (en) | Inhibitors of Bruton's tyrosine kinase | |
GB0807642D0 (en) | IKK- serine-threonine protein kinase inhibitors |